This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAboutAboutHow TRUMENBA WorksTru Patient StoriesAre Your Patients Protected?CDC RecommendationsDosingEfficacy & SafetyEfficacy & SafetySafety Profile and TolerabilityImmunogenicity & PersistenceSupport & OrderSupport & OrderEventsMaterialsVideosWelcome to TruSupportOrdering & InventoryCoverage & ReimbursementPatient Adherence
Prescribing InformationIndicationMedical Information
Immunogenicity & PersistenceTRUMENBA® was the FIRST MenB vaccine with proven protection against diverse strains1
TRUMENBA demonstrated robust immune response against 14 MenB strains found in the US and Europe1
TRUMENBA provides proven protection against diverse MenB strains, which is important because you don't know which of the >1800 MenB strains your patients may encounter1,5Based on demonstrated effectiveness against 14 diverse strains representative of prevalent MenB strains.1Study 1 was a Phase 3, randomized, active-controlled, observer-blinded trial in adolescents 10 to 25 years of age (n=1057). Study 2 was a Phase 3, randomized, active-controlled, observer-blinded trial in adolescents 10 to 18 years of age (n=2693), and study 3 was a Phase 3, randomized, placebo-controlled, observer-blinded trial in young adults 18 to 25 years of age (n=2471). Studies 1 and 2 were conducted in the United States, Canada, and Europe. In study 1, subjects received 2 doses of TRUMENBA on a 0- and 6-month schedule, and in studies 2 and 3, subjects received 3 doses of TRUMENBA on a 0-, 2-, and 6-month schedule.1,6To achieve a 4-fold increase in immune response to TRUMENBA, a minimum hSBA (serum bactericidal activity using human complement) titer of 1:16 was measured if baseline hSBA titer was <1:4; in subjects with a baseline titer of ≥1:4, an hSBA titer ≥4 times an hSBA titer ≥1:8 (1:16 for strain A22) or ≥4 times the baseline titer, whichever was higher.1,6​​​​​​​1:8 for A07, A15, A29, B03, B09, B15, and B16; 1:16 for A06, A12, and A19.1,6TRUMENBA can help protect adolescents and young adults during their peak risk years7-10fHbp=factor H binding protein; hSBA=serum bactericidal activity using human complement; MenB=serogroup B meningococcal disease.Title
Contact your Pfizer Sales Representative or call a Vaccine Specialist at 1-800-666-7248.
References:1. TRUMENBA® (Meningococcal Group B Vaccine). Prescribing information. Pfizer; 2024. 2. Data on file. QuintilesIMS Primary Research Market Study, 2017. 3. McDaniel A, Dempsey A, Srivastana A. A physician’s guide to the 2-dose schedule of MenB-FHbp vaccine. Hum Vaccin Immunother. 2019;15(11):2729-2737. 4. Burman C, Serra L, Nuttens C, et al. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Hum Vaccin Immunother. 2019;15(2):459-469. 5. Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200(3):379-389. 6. Østergaard L, Vesikari T, Senders SD, et al. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months. Vaccine. 2021;39(32):4545-4554. 7. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450. 8. Centers for Disease Control and Prevention. Meningococcal disease. Updated February 1, 2024. Accessed January 13, 2025. https://www.cdc.gov/meningococcal/risk-factors/index.html 9. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9. 10. Balmer P, Burman C, Serra L, York LJ. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118-1130. 11. Data on file. Clinical Study Report Protocol B1971033: Pfizer Inc, New York, NY. 12. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1–41. 13. Vesikari T, Østergaard L, Diez-Domingo J, et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatr Infect Dis Soc. 2016;5(2):152-160.Efficacy & Safety Pfizer TruSupport
  • Ordering options
  • Patient coverage confirmation
  • Essential tools
  • Resources for your practice
 Find out about TruSupport Loading Why adolescents and young adults?

Typical adolescent and young adult behaviors increase MenB risk.7-10

 Learn more about MenB Loading
The science behind TRUMENBA

Only TRUMENBA targets both subfamilies, A and B, of fHbp.1

 See the scienceLoading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-TRU-USA-3203
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

INDICATION
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Important Safety Information
  • Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
  • Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%) 
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness have not been established in pregnant women
Indication
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Please see full Prescribing Information.